The Psychological and Social Burden of Psoriasis

Psoriasis exerts a psychological toll that is frequently disproportionate to the physical severity of the disease. A patient with limited disease on the hands, face, or genitals may experience greater psychological distress than a patient with extensive disease on the trunk and limbs. Understanding the mental health dimensions of psoriasis is essential for holistic care.

16.1 Depression

Depression is the most-studied psychiatric comorbidity in psoriasis. A landmark UK population-based cohort study (n = 146,042 psoriasis patients vs. 766,950 controls) found adjusted hazard ratios for depression of 1.39 overall (95% CI 1.37–1.41), rising to 1.72 for severe psoriasis (95% CI 1.57–1.88). The authors estimated that, in the UK alone, over 10,400 diagnoses of depression per year are attributable to psoriasis (Kurd et al., 2010). A systematic review and meta-analysis found that approximately 28% of psoriasis patients report depressive symptoms on screening questionnaires, and 12–19% meet formal clinical diagnostic criteria for depression (Dowlatshahi et al., 2014). Depression is more prevalent among women with psoriasis and among those with more severe disease, psoriatic arthritis, or multiple comorbidities.

The relationship is likely bidirectional. Psoriasis causes depression through psychological and social mechanisms: stigma, shame, restricted activities, relationship difficulties, reduced employment. But depression may also worsen psoriasis through biological pathways. Proinflammatory cytokines elevated in psoriasis, including IL-1, IL-6, and IL-17, are also elevated in major depressive disorder, suggesting shared inflammatory mechanisms. In a secondary analysis of two large RCTs, ixekizumab (an anti-IL-17A antibody) produced both depression remission and reduction in serum CRP in patients with comorbid psoriasis and moderate-to-severe depression, supporting a neuroinflammatory link (Griffiths et al., 2017).

16.2 Suicidal Ideation and Suicide

The relationship between psoriasis and suicidality has been examined in multiple systematic reviews with somewhat conflicting results. The UK cohort study above found an adjusted hazard ratio for suicidality of 1.44 (95% CI 1.32–1.57). A well-controlled pan-European study of 3,635 dermatological patients across 13 countries (including a psoriasis subgroup) reported an approximately twofold greater risk of suicidal ideation compared to controls (adjusted OR 1.94, 95% CI 1.33–2.82) (Dalgard et al., 2015). Among tertiary patients with moderate-to-severe disease, up to 49% report lifetime suicidal thoughts (Lada et al., 2022).

The 2025 BADBIR analysis (British Association of Dermatologists Biologics and Immunomodulators Register) specifically examined suicide risk in patients with clinically confirmed moderate-to-severe psoriasis (Williams et al., 2025). Patients with a history of psychiatric comorbidity had significantly increased rates of all suicidality outcomes. However, the overall suicide rate among psoriasis patients was not significantly elevated compared to the general population. The authors emphasised the high prevalence of undiagnosed depression and the need for routine mental health assessment at every dermatology appointment.

16.3 Anxiety Disorders

Anxiety has received less attention than depression in psoriasis research, but it may be even more prevalent. A meta-analysis of 101 studies found that approximately 21% of psoriasis patients meet diagnostic criteria for a clinical anxiety disorder, and up to 43% report elevated anxiety symptoms on screening questionnaires (Fleming et al., 2017). The most common presentations include generalised anxiety disorder, social anxiety disorder, and health anxiety.

Social anxiety is particularly relevant. The visibility of psoriasis creates a specific type of anticipatory dread: worry about being stared at, asked intrusive questions, or rejected. Patients with psoriasis on visible sites (hands, face, scalp) report higher anxiety than those with trunk-limited disease, regardless of total BSA. Social anxiety drives avoidance behaviours (declining invitations, changing clothing choices, avoiding intimacy) that compound the quality-of-life burden.

Health anxiety in psoriasis takes several forms: fear of disease progression, worry about medication side effects, and anxiety about passing the condition to children. These concerns aren’t irrational given psoriasis’s chronic nature and real comorbidity burden (Section 14), but when they become disproportionate and disabling, they warrant treatment.

The bidirectional relationship between anxiety and psoriasis mirrors that of depression: anxiety triggers the stress-inflammation axis (Section 8.3), which can worsen skin disease, which in turn worsens anxiety. Clinicians should screen for anxiety alongside depression, using validated tools such as the GAD-7.

The Brodalumab Suicidality Signal

Brodalumab (Siliq), an IL-17 receptor blocker, carries a boxed warning for suicidal ideation and behaviour. This stems from four completed suicides during its clinical trial programme (three in the psoriasis trials, one in the PsA trial). The context matters, though. All four individuals had pre-existing psychiatric comorbidities. Post-marketing surveillance and large cohort analyses haven’t confirmed a causal link between brodalumab and suicidality beyond what would be expected in a severe psoriasis population with high baseline psychiatric comorbidity (Lebwohl et al., 2020). A pooled safety analysis of over 4,000 brodalumab-treated patients found suicide rates consistent with those in the general psoriasis population.

The practical consequence is that brodalumab requires a Risk Evaluation and Mitigation Strategy (REMS) programme in the US, limiting its prescribing to certified healthcare settings. Whether the boxed warning reflects a true drug effect or the background psychiatric burden of severe psoriasis remains debated. What’s not debated: any patient starting systemic psoriasis therapy should be screened for depression and suicidal ideation, regardless of which drug they’re prescribed.

Unlike many chronic diseases, psoriasis is visible. Patients report being stared at, refused service at hairdressers and swimming pools, asked whether their condition is contagious, and experiencing rejection in intimate relationships. A concept termed “social skin” has been used in the dermatology literature to describe how the skin mediates social identity and interpersonal connection, and how visible skin disease disrupts this.

The WHO’s 2016 Global Report on Psoriasis highlighted that patients frequently feel humiliated, stigmatised, and socially excluded, and called on governments to recognise psoriasis as a serious non-communicable disease. The report noted that patients with psoriasis often change their behaviour to avoid situations where their skin might be visible: avoiding swimming, changing how they dress, declining social invitations, and withdrawing from sexual relationships.

16.5 Impact on Employment and Productivity

Psoriasis significantly affects working life. Studies using the Work Productivity and Activity Impairment (WPAI) questionnaire have documented that patients with moderate-to-severe psoriasis experience substantial work impairment, with total productivity losses of 19–29% of working time depending on disease severity. That’s equivalent to approximately one to two lost working days per week (Korman et al., 2016). Career limitation is common: patients report avoiding certain professions, declining promotions that involve public visibility, and taking early retirement.

Hand psoriasis and occupational challenges. Psoriasis affecting the hands is particularly disabling for employment. Manual workers, healthcare professionals, food handlers, and those in any occupation requiring frequent hand washing or wet work face both functional impairment (painful cracking, reduced grip strength) and social barriers (colleagues’ and customers’ reactions to visible lesions). Occupational dermatology services can provide workplace assessments and recommendations.

Legal protections. In the UK, psoriasis can qualify as a disability under the Equality Act 2010 if it has a “substantial and long-term adverse effect” on a person’s ability to carry out normal day-to-day activities. In the US, severe psoriasis may be covered under the Americans with Disabilities Act (ADA). Reasonable workplace adjustments may include flexible working arrangements, access to private changing facilities, modified dress codes, and time off for treatment appointments.

Employer communication. Patients often struggle with whether and how to disclose their condition to employers. Advocacy organisations (Appendix A2) provide template letters and guidance for workplace conversations. Where possible, involving the occupational health department can facilitate appropriate adjustments without requiring the patient to disclose details to managers or colleagues directly.

16.6 Psychological Interventions

Growing evidence supports incorporating psychological support into psoriasis care. Cognitive behavioural therapy (CBT), mindfulness-based stress reduction (MBSR), and habit reversal training (for itch-scratch cycles) have all shown benefit in small trials. One landmark early study found that psoriasis patients who listened to mindfulness meditation tapes during phototherapy sessions achieved skin clearing significantly faster than those receiving phototherapy alone (Kabat-Zinn et al., 1998). Current guidelines increasingly advocate routine mental health screening, using validated tools such as the PHQ-2 or PHQ-9 for depression and asking about suicidal ideation, at every dermatology appointment, particularly when starting, changing, or reviewing systemic treatment.